Caveats of caveolin-1 in cancer progression

Cancer Letters

Volumn 268, Issue 2, 2008, Pages 187-201

  Burgermeister, Elke ^a   Liscovitch, Mordechai ^b   Röcken, Christoph ^c   Schmid, Roland M ^a   Ebert, Matthias P A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; Cancer progression; Caveolin; Metastasis; Prognosis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CATENIN; CATHEPSIN B; CAVEOLIN 1; CLAUDIN; COLLAGENASE 3; DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; JANUS KINASE; OCCLUDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; PROTEIN KINASE B; PROTEIN ZO1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SCAFFOLD PROTEIN; SCATTER FACTOR; STAT PROTEIN; STROMELYSIN 3; SUPPRESSOR OF CYTOKINE SIGNALING; UNINDEXED DRUG; UVOMORULIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; BILE DUCT TUMOR; BLADDER TUMOR; BRAIN TUMOR; BREAST TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CELL COMPARTMENTALIZATION; CELL SURVIVAL; CELL TRANSPORT; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; COLON TUMOR; DISEASE FREE SURVIVAL; EWING SARCOMA; EXTRACELLULAR MATRIX; GASTROINTESTINAL TUMOR; GLIOMA; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG TUMOR; MENINGIOMA; METASTASIS; MOLECULAR BIOLOGY; MOUTH TUMOR; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE TUMOR; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; RADIOSENSITIVITY; SALIVARY GLAND TUMOR; SHORT SURVEY; STOMACH TUMOR; THYROID TUMOR; TUMOR SUPPRESSOR GENE; VASCULAR SMOOTH MUSCLE;

RODENTIA;

EID: 48549100790     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.055     Document Type: Review

References (162)

1. Parton R.G., and Simons K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8 (2007) 185-194
2. Williams T.M., and Lisanti M.P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. Cell Physiol. 288 (2005) C494-C506
3. Cohen A.W., Hnasko R., Schubert W., and Lisanti M.P. Role of caveolae and caveolins in health and disease. Physiol. Rev. 84 (2004) 1341-1379
4. Michel V., and Bakovic M. Lipid rafts in health and disease. Biol. Cell 99 (2007) 129-140
5. Sanna E., Miotti S., Mazzi M., De Santis G., Canevari S., and Tomassetti A. Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. Exp. Cell Res. 313 (2007) 1307-1317
6. Patel H.H., Murray F., and Insel P.A. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu. Rev. Pharmacol. Toxicol. (2007)
7. Hnasko R., and Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol. Interv. 3 (2003) 445-464
8. Le Lay S., and Kurzchalia T.V. Getting rid of caveolins: phenotypes of caveolin-deficient animals. Biochim. Biophys. Acta 1746 (2005) 322-333
9. Juhasz M., Chen J., Tulassay Z., Malfertheiner P., and Ebert M.P. Expression of caveolin-1 in gastrointestinal and extraintestinal cancers. J. Cancer Res. Clin. Oncol. 129 (2003) 493-497
10. M. Liscovitch, E. Burgermeister, N. Jain, D. Ravid, M. Shatz, L. Tencer, Caveolin and cancer: a complex relationship, in: M.P. Mattson (Ed.), Membrane Microdomain Signaling: Lipid Rafts in Biology and Medicine, Humana Press, Totowa, NJ, 2004, pp. 161-190.
11. Ando T., Ishiguro H., Kimura M., Mitsui A., Mori Y., Sugito N., Tomoda K., Mori R., Harada K., Katada T., Ogawa R., Fujii Y., and Kuwabara Y. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol. Rep. 18 (2007) 601-609
12. Yoo S.H., Park Y.S., Kim H.R., Sung S.W., Kim J.H., Shim Y.S., Lee S.D., Choi Y.L., Kim M.K., and Chung D.H. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42 (2003) 195-202
13. Lavie Y., Fiucci G., and Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem. 273 (1998) 32380-32383
14. Yang C.P., Galbiati F., Volonte D., Horwitz S.B., and Lisanti M.P. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 439 (1998) 368-372
15. Belanger M.M., Roussel E., and Couet J. Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 14 (2003) 281-287
16. Karam J.A., Lotan Y., Roehrborn C.G., Ashfaq R., Karakiewicz P.I., and Shariat S.F. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67 (2007) 614-622
17. Satoh T., Yang G., Egawa S., Addai J., Frolov A., Kuwao S., Timme T.L., Baba S., and Thompson T.C. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97 (2003) 1225-1233
18. Joo H.J., Oh D.K., Kim Y.S., Lee K.B., and Kim S.J. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 93 (2004) 291-296
19. Yang G., Addai J., Wheeler T.M., Frolov A., Miles B.J., Kadmon D., and Thompson T.C. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum. Pathol. 38 (2007) 1688-1695
20. Ho C.C., Huang P.H., Huang H.Y., Chen Y.H., Yang P.C., and Hsu S.M. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am. J. Pathol. 161 (2002) 1647-1656
21. Kato T., Miyamoto M., Kato K., Cho Y., Itoh T., Morikawa T., Okushiba S., Kondo S., Ohbuchi T., and Katoh H. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett. 214 (2004) 121-128
22. Campbell L., Gumbleton M., and Griffiths D.F. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br. J. Cancer 89 (2003) 1909-1913
23. Horiguchi A., Asano T., Asakuma J., Sumitomo M., and Hayakawa M. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J. Urol. 172 (2004) 718-722
24. Kato K., Hida Y., Miyamoto M., Hashida H., Shinohara T., Itoh T., Okushiba S., Kondo S., and Katoh H. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94 (2002) 929-933
25. Ho C.C., Kuo S.H., Huang P.H., Huang H.Y., Yang C.H., and Yang P.C. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer (2007)
26. Tahir S.A., Ren C., Timme T.L., Gdor Y., Hoogeveen R., Morrisett J.D., Frolov A., Ayala G., Wheeler T.M., and Thompson T.C. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin. Cancer Res. 9 (2003) 3653-3659
27. Tahir S.A., Frolov A., Hayes T.G., Mims M.P., Miles B.J., Lerner S.P., Wheeler T.M., Ayala G., Thompson T.C., and Kadmon D. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin. Cancer Res. 12 (2006) 4872-4875
28. Murakami S., Miyamoto M., Hida Y., Cho Y., Fukunaga A., Oshikiri T., Kato K., Kurokawa T., Suzuoki M., Nakakubo Y., Hiraoka K., Itoh T., Shinohara T., Morikawa T., Okushiba O., Kondo S., and Katoh H. Caveolin-I overexpression is a favourable prognostic factor for patients with extrahepatic bile duct carcinoma. Br. J. Cancer 88 (2003) 1234-1238
29. Shi L., Chen X.M., Wang L., Zhang L., and Chen Z. Expression of caveolin-1 in mucoepidermoid carcinoma of the salivary glands: correlation with vascular endothelial growth factor, microvessel density, and clinical outcome. Cancer 109 (2007) 1523-1531
30. Park S.S., Kim J.E., Kim Y.A., Kim Y.C., and Kim S.W. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 47 (2005) 625-630
31. Sagara Y., Mimori K., Yoshinaga K., Tanaka F., Nishida K., Ohno S., Inoue H., and Mori M. Clinical significance of caveolin-1, caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br. J. Cancer 91 (2004) 959-965
32. Davidson B., Nesland J.M., Goldberg I., Kopolovic J., Gotlieb W.H., Bryne M., Ben-Baruch G., Berner A., and Reich R. Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study. Gynecol. Oncol. 81 (2001) 166-171
33. Burgermeister E., Xing X., Rocken C., Juhasz M., Chen J., Hiber M., Mair K., Shatz M., Liscovitch M., Schmid R.M., and Ebert M.P. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res. 67 (2007) 8519-8526
34. van Golen K.L. Is caveolin-1 a viable therapeutic target to reduce cancer metastasis?. Expert Opin. Ther. Targets 10 (2006) 709-721
35. Navarro A., Anand-Apte B., and Parat M.O. A role for caveolae in cell migration. FASEB J. 18 (2004) 1801-1811
36. Miotti S., Tomassetti A., Facetti I., Sanna E., Berno V., and Canevari S. Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am. J. Pathol. 167 (2005) 1411-1427
37. Schwarz B.T., Wang F., Shen L., Clayburgh D.R., Su L., Wang Y., Fu Y.X., and Turner J.R. LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology 132 (2007) 2383-2394
38. Song L., Ge S., and Pachter J.S. Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells. Blood 109 (2007) 1515-1523
39. Nag S., Venugopalan R., and Stewart D.J. Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown. Acta Neuropathol. (Berl.) 114 (2007) 459-469
40. Nusrat A., Parkos C.A., Verkade P., Foley C.S., Liang T.W., Innis-Whitehouse W., Eastburn K.K., and Madara J.L. Tight junctions are membrane microdomains. J. Cell Sci. 113 Pt. 10 (2000) 1771-1781
41. Galbiati F., Volonte D., Brown A.M., Weinstein D.E., Ben-Ze'ev A., Pestell R.G., and Lisanti M.P. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J. Biol. Chem. 275 (2000) 23368-23377
42. Lu Z., Ghosh S., Wang Z., and Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4 (2003) 499-515
43. Shen L., and Turner J.R. Actin depolymerization disrupts tight junctions via caveolae-mediated endocytosis. Mol. Biol. Cell 16 (2005) 3919-3936
44. Akhtar N., and Hotchin N.A. RAC1 regulates adherens junctions through endocytosis of E-cadherin. Mol. Biol. Cell 12 (2001) 847-862
45. Salanueva I.J., Cerezo A., Guadamillas M.C., and Del Pozo M.A. Integrin regulation of caveolin function. J. Cell. Mol. Med. 11 (2007) 969-980
46. Del Pozo M.A., and Schwartz M.A. Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends Cell Biol. 17 (2007) 246-250
47. del Pozo M.A., Balasubramanian N., Alderson N.B., Kiosses W.B., Grande-Garcia A., Anderson R.G., and Schwartz M.A. Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat. Cell Biol. 7 (2005) 901-908
48. Sedding D.G., Hermsen J., Seay U., Eickelberg O., Kummer W., Schwencke C., Strasser R.H., Tillmanns H., and Braun-Dullaeus R.C. Caveolin-1 facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo. Circ. Res. 96 (2005) 635-642
49. Cordes N., Frick S., Brunner T.B., Pilarsky C., Grutzmann R., Sipos B., Kloppel G., McKenna W.G., and Bernhard E.J. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26 (2007) 6851-6862
50. Fiucci G., Ravid D., Reich R., and Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21 (2002) 2365-2375
51. Ravid D., Maor S., Werner H., and Liscovitch M. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 24 (2005) 1338-1347
52. Glait C., Tencer L., Ravid D., Sarfstein R., Liscovitch M., and Werner H. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp. Cell Res. 312 (2006) 3899-3908
53. Kim H.A., Kim K.H., and Lee R.A. Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues. Exp. Mol. Pathol. 80 (2006) 165-170
54. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
55. Engelman J.A., Zhang X.L., and Lisanti M.P. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 436 (1998) 403-410
56. Hellman A., Zlotorynski E., Scherer S.W., Cheung J., Vincent J.B., Smith D.I., Trakhtenbrot L., and Kerem B. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 1 (2002) 89-97
57. Han S.Y., Druck T., and Huebner K. Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics 81 (2003) 105-107
58. Garcia S., Dales J.P., Charafe-Jauffret E., Carpentier-Meunier S., Andrac-Meyer L., Jacquemier J., Andonian C., Lavaut M.N., Allasia C., Bonnier P., and Charpin C. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum. Pathol. 38 (2007) 830-841
59. Hu Y.C., Lam K.Y., Law S., Wong J., and Srivastava G. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin. Cancer Res. 7 (2001) 3519-3525
60. Zhang X., Ling M.T., Wang Q., Lau C.K., Leung S.C., Lee T.K., Cheung A.L., Wong Y.C., and Wang X. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J. Biol. Chem. 282 (2007) 33284-33294
61. Cavallo-Medved D., Mai J., Dosescu J., Sameni M., and Sloane B.F. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J. Cell Sci. 118 (2005) 1493-1503
62. Stahl A., and Mueller B.M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol. 129 (1995) 335-344
63. Lopez-Rivera E., Lizarbe T.R., Martinez-Moreno M., Lopez-Novoa J.M., Rodriguez-Barbero A., Rodrigo J., Fernandez A.P., Alvarez-Barrientos A., Lamas S., and Zaragoza C. Matrix metalloproteinase 13 mediates nitric oxide activation of endothelial cell migration. Proc. Natl. Acad. Sci. USA 102 (2005) 3685-3690
64. Labrecque L., Nyalendo C., Langlois S., Durocher Y., Roghi C., Murphy G., Gingras D., and Beliveau R. Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J. Biol. Chem. 279 (2004) 52132-52140
65. Annabi B., Thibeault S., Moumdjian R., and Beliveau R. Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J. Biol. Chem. 279 (2004) 21888-21896
66. Tang W., and Hemler M.E. Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering. J. Biol. Chem. 279 (2004) 11112-11118
67. Puyraimond A., Fridman R., Lemesle M., Arbeille B., and Menashi S. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp. Cell Res. 262 (2001) 28-36
68. Jia L., Wang S., Zhou H., Cao J., Hu Y., and Zhang J. Caveolin-1 up-regulates CD147 glycosylation and the invasive capability of murine hepatocarcinoma cell lines. Int. J. Biochem. Cell Biol. 38 (2006) 1584-1593
69. Galvez B.G., Matias-Roman S., Yanez-Mo M., Vicente-Manzanares M., Sanchez-Madrid F., and Arroyo A.G. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol. Biol. Cell 15 (2004) 678-687
70. Sotgia F., Williams T.M., Schubert W., Medina F., Minetti C., Pestell R.G., and Lisanti M.P. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am. J. Pathol. 168 (2006) 292-309
71. Williams T.M., Medina F., Badano I., Hazan R.B., Hutchinson J., Muller W.J., Chopra N.G., Scherer P.E., Pestell R.G., and Lisanti M.P. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279 (2004) 51630-51646
72. Chow A.K., Cena J., El-Yazbi A.F., Crawford B.D., Holt A., Cho W.J., Daniel E.E., and Schulz R. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J. Mol. Cell. Cardiol. 42 (2007) 896-901
73. Fang K., Fu W., Beardsley A.R., Sun X., Lisanti M.P., and Liu J. Overexpression of caveolin-1 inhibits endothelial cell proliferation by arresting the cell cycle at G0/G1 phase. Cell Cycle 6 (2007) 199-204
74. Hassan G.S., Williams T.M., Frank P.G., and Lisanti M.P. Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H2393-H2401
75. Liu J., Razani B., Tang S., Terman B.I., Ware J.A., and Lisanti M.P. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J. Biol. Chem. 274 (1999) 15781-15785
76. Liu J., Wang X.B., Park D.S., and Lisanti M.P. Caveolin-1 expression enhances endothelial capillary tubule formation. J. Biol. Chem. 277 (2002) 10661-10668
77. Massimino M.L., Griffoni C., Spisni E., Toni M., and Tomasi V. Involvement of caveolae and caveolae-like domains in signalling, cell survival and angiogenesis. Cell. Signal. 14 (2002) 93-98
78. Griffoni C., Spisni E., Santi S., Riccio M., Guarnieri T., and Tomasi V. Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem. Biophys. Res. Commun. 276 (2000) 756-761
79. Beardsley A., Fang K., Mertz H., Castranova V., Friend S., and Liu J. Loss of caveolin-1 polarity impedes endothelial cell polarization and directional movement. J. Biol. Chem. 280 (2005) 3541-3547
80. Woodman S.E., Ashton A.W., Schubert W., Lee H., Williams T.M., Medina F.A., Wyckoff J.B., Combs T.P., and Lisanti M.P. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am. J. Pathol. 162 (2003) 2059-2068
81. Sonveaux P., Martinive P., DeWever J., Batova Z., Daneau G., Pelat M., Ghisdal P., Gregoire V., Dessy C., Balligand J.L., and Feron O. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ. Res. 95 (2004) 154-161
82. Sbaa E., Dewever J., Martinive P., Bouzin C., Frerart F., Balligand J.L., Dessy C., and Feron O. Caveolin plays a central role in endothelial progenitor cell mobilization and homing in SDF-1-driven postischemic vasculogenesis. Circ. Res. 98 (2006) 1219-1227
83. Dewever J., Frerart F., Bouzin C., Baudelet C., Ansiaux R., Sonveaux P., Gallez B., Dessy C., and Feron O. Caveolin-1 is critical for the maturation of tumor blood vessels through the regulation of both endothelial tube formation and mural cell recruitment. Am. J. Pathol. 171 (2007) 1619-1628
84. Jasmin J.F., Malhotra S., Singh Dhallu M., Mercier I., Rosenbaum D.M., and Lisanti M.P. Caveolin-1 deficiency increases cerebral ischemic injury. Circ. Res. 100 (2007) 721-729
85. Murata T., Lin M.I., Huang Y., Yu J., Bauer P.M., Giordano F.J., and Sessa W.C. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J. Exp. Med. 204 (2007) 2373-2382
86. Choi H.N., Kim K.R., Park H.S., Jang K.Y., Kang M.J., Lee D.G., Kim Y.K., Cho B.H., Cha E.J., and Moon W.S. Expression of caveolin in hepatocellular carcinoma: association with unpaired artery formation and radiologic findings. Korean J. Hepatol. 13 (2007) 396-408
87. Lin M.I., Yu J., Murata T., and Sessa W.C. Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res. 67 (2007) 2849-2856
88. Galvagni F., Anselmi F., Salameh A., Orlandini M., Rocchigiani M., and Oliviero S. Vascular endothelial growth factor receptor-3 activity is modulated by its association with caveolin-1 on endothelial membrane. Biochemistry 46 (2007) 3998-4005
89. Gratton J.P., Lin M.I., Yu J., Weiss E.D., Jiang Z.L., Fairchild T.A., Iwakiri Y., Groszmann R., Claffey K.P., Cheng Y.C., and Sessa W.C. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4 (2003) 31-39
90. Bucci M., Gratton J.P., Rudic R.D., Acevedo L., Roviezzo F., Cirino G., and Sessa W.C. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6 (2000) 1362-1367
91. Bernatchez P.N., Bauer P.M., Yu J., Prendergast J.S., He P., and Sessa W.C. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc. Natl. Acad. Sci. USA 102 (2005) 761-766
92. Jasmin J.F., Mercier I., Sotgia F., and Lisanti M.P. SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrinol. Metab. 17 (2006) 150-158
93. Jourdan Le Saux C.T., Teeters K.M., Miyasato S.K., Hoffmann P.R., Bollt O.M., Douet V., Shohet R.V., Broide D.H., and Tam E.K. Down-regulation of caveolin-1, an inhibitor of TGF-beta signaling, in acute allergen-induced airway remodeling. J. Biol. Chem. (2007)
94. Garrean S., Gao X.P., Brovkovych V., Shimizu J., Zhao Y.Y., Vogel S.M., and Malik A.B. Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J. Immunol. 177 (2006) 4853-4860
95. Medina F.A., de Almeida C.J., Dew E., Li J., Bonuccelli G., Williams T.M., Cohen A.W., Pestell R.G., Frank P.G., Tanowitz H.B., and Lisanti M.P. Caveolin-1-deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar Typhimurium infection. Infect. Immun. 74 (2006) 6665-6674
96. Medina F.A., Cohen A.W., de Almeida C.J., Nagajyothi F., Braunstein V.L., Teixeira M.M., Tanowitz H.B., and Lisanti M.P. Immune dysfunction in caveolin-1 null mice following infection with Trypanosoma cruzi (Tulahuen strain). Microbes Infect. 9 (2007) 325-333
97. Hu G., Ye R.D., Dinauer M.C., Malik A.B., and Minshall R.D. Neutrophil caveolin-1 expression contributes to the mechanism of lung inflammation and injury. Am. J. Physiol. Lung Cell. Mol. Physiol. (2007)
98. Bouzin C., Brouet A., De Vriese J., Dewever J., and Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol. 178 (2007) 1505-1511
99. Millan J., Hewlett L., Glyn M., Toomre D., Clark P., and Ridley A.J. Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains. Nat. Cell Biol. 8 (2006) 113-123
100. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
101. Lugini L., Matarrese P., Tinari A., Lozupone F., Federici C., Iessi E., Gentile M., Luciani F., Parmiani G., Rivoltini L., Malorni W., and Fais S. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 66 (2006) 3629-3638
102. Fais S. Cannibalism: a way to feed on metastatic tumors. Cancer Lett. 258 (2007) 155-164
103. Ravid D., Maor S., Werner H., and Liscovitch M. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv. Enzyme Regul. 46 (2006) 163-175
104. Burgermeister E., Tencer L., and Liscovitch M. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 22 (2003) 3888-3900
105. Llaverias G., Vazquez-Carrera M., Sanchez R.M., Noe V., Ciudad C.J., Laguna J.C., and Alegret M. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J. Lipid Res. 45 (2004) 2015-2024
106. Chintharlapalli S., Smith III R., Samudio I., Zhang W., and Safe S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res. 64 (2004) 5994-6001
107. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., Rao M.S., Gonzalez F.J., and Reddy J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 278 (2003) 498-505
108. Schlegel A., Wang C., Katzenellenbogen B.S., Pestell R.G., and Lisanti M.P. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. Caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J. Biol. Chem. 274 (1999) 33551-33556
109. Lu M.L., Schneider M.C., Zheng Y., Zhang X., and Richie J.P. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J. Biol. Chem. 276 (2001) 13442-13451
110. Xia W., Bacus S., Hegde P., Husain I., Strum J., Liu L., Paulazzo G., Lyass L., Trusk P., Hill J., Harris J., and Spector N.L. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA 103 (2006) 7795-7800
111. van den Heuvel A.P., Schulze A., and Burgering B.M. Direct control of caveolin-1 expression by FOXO transcription factors. Biochem. J. 385 (2005) 795-802
112. Radel C., and Rizzo V. Integrin mechanotransduction stimulates caveolin-1 phosphorylation and recruitment of Csk to mediate actin reorganization. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H936-H945
113. Yu J., Bergaya S., Murata T., Alp I.F., Bauer M.P., Lin M.I., Drab M., Kurzchalia T.V., Stan R.V., and Sessa W.C. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J. Clin. Invest. 116 (2006) 1284-1291
114. Frank P.G., and Lisanti M.P. Role of caveolin-1 in the regulation of the vascular shear stress response. J. Clin. Invest. 116 (2006) 1222-1225
115. Sanguinetti A.R., Cao H., and Corley Mastick C. Fyn is required for oxidative- and hyperosmotic-stress-induced tyrosine phosphorylation of caveolin-1. Biochem. J. 376 (2003) 159-168
116. Uittenbogaard A., and Smart E.J. Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J. Biol. Chem. 275 (2000) 25595-25599
117. Li W.P., Liu P., Pilcher B.K., and Anderson R.G. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J. Cell Sci. 114 (2001) 1397-1408
118. Liu P., Li W.P., Machleidt T., and Anderson R.G. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat. Cell Biol. 1 (1999) 369-375
119. Sawada N., Taketani Y., Amizuka N., Ichikawa M., Ogawa C., Nomoto K., Nashiki K., Sato T., Arai H., Isshiki M., Segawa H., Yamamoto H., Miyamoto K., and Takeda E. Caveolin-1 in extracellular matrix vesicles secreted from osteoblasts. Bone 41 (2007) 52-58
120. Bartz R., Zhou J., Hsieh J.T., Ying Y., Li W., and Liu P. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int. J. Cancer (2007)
121. Ayala G.E., Dai H., Tahir S.A., Li R., Timme T., Ittmann M., Frolov A., Wheeler T.M., Rowley D., and Thompson T.C. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 66 (2006) 5159-5164
122. Shatz M., and Liscovitch M. Caveolin-1 and cancer multidrug resistance: coordinate regulation of pro-survival proteins?. Leuk. Res. 28 (2004) 907-908
123. Nakatani K., Wada T., Nakamura M., Uzawa K., Tanzawa H., and Fujita S. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 131 (2005) 445-452
124. Li J., Hassan G.S., Williams T.M., Minetti C., Pestell R.G., Tanowitz H.B., Frank P.G., Sotgia F., and Lisanti M.P. Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle 4 (2005) 1817-1825
125. Sotgia F., Williams T.M., Cohen A.W., Minetti C., Pestell R.G., and Lisanti M.P. Caveolin-1-deficient mice have an increased mammary stem cell population with upregulation of Wnt/beta-catenin signaling. Cell Cycle 4 (2005) 1808-1816
126. Sotgia F., Rui H., Bonuccelli G., Mercier I., Pestell R.G., and Lisanti M.P. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res. 66 (2006) 10647-10651
127. Selleri S., Arnaboldi F., Palazzo M., Hussein U., Balsari A., and Rumio C. Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. Br. J. Dermatol. 153 (2005) 506-513
128. Rubin J., Schwartz Z., Boyan B.D., Fan X., Case N., Sen B., Drab M., Smith D., Aleman M., Wong K.L., Yao H., Jo H., and Gross T.S. Caveolin-1 knockout mice have increased bone size and stiffness. J. Bone Miner. Res. 22 (2007) 1408-1418
129. Marbeuf-Gueye C., Stierle V., Sudwan P., Salerno M., and Garnier-Suillerot A. Perturbation of membrane microdomains in GLC4 multidrug-resistant lung cancer cells - modification of ABCC1 (MRP1) localization and functionality. FEBS J. 274 (2007) 1470-1480
130. Ronaldson P.T., Bendayan M., Gingras D., Piquette-Miller M., and Bendayan R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J. Neurochem. 89 (2004) 788-800
131. Barakat S., Demeule M., Pilorget A., Regina A., Gingras D., Baggetto L.G., and Beliveau R. Modulation of p-glycoprotein function by caveolin-1 phosphorylation. J. Neurochem. 101 (2007) 1-8
132. Jodoin J., Demeule M., Fenart L., Cecchelli R., Farmer S., Linton K.J., Higgins C.F., and Beliveau R. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J. Neurochem. 87 (2003) 1010-1023
133. Zhu H., Cai C., and Chen J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Lett. 576 (2004) 369-374
134. Cai C., and Chen J. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int. J. Cancer 111 (2004) 522-529
135. Regina A., Jodoin J., Khoueir P., Rolland Y., Berthelet F., Moumdjian R., Fenart L., Cecchelli R., Demeule M., and Beliveau R. Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy. J. Neurosci. Res. 75 (2004) 291-299
136. Pang A., Au W.Y., and Kwong Y.L. Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leuk. Res. 28 (2004) 973-977
137. Jasmin J.F., Mercier I., Dupuis J., Tanowitz H.B., and Lisanti M.P. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 114 (2006) 912-920
138. Hung K.F., Lin S.C., Liu C.J., Chang C.S., Chang K.W., and Kao S.Y. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J. Oral Pathol. Med. 32 (2003) 461-467
139. Shin J., Kim J., Ryu B., Chi S.G., and Park H. Caveolin-1 is associated with VCAM-1 dependent adhesion of gastric cancer cells to endothelial cells. Cell. Physiol. Biochem. 17 (2006) 211-220
140. Gao X., Sun Y., Huang L., Chen X.Y., Zhang K.L., Kong Q.Y., Liu J., and Li H. Down-regulation of caveolin-1 in gastric carcinoma and its clinical biological significance. Ai Zheng 24 (2005) 311-316
141. Suzuoki M., Miyamoto M., Kato K., Hiraoka K., Oshikiri T., Nakakubo Y., Fukunaga A., Shichinohe T., Shinohara T., Itoh T., Kondo S., and Katoh H. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br. J. Cancer 87 (2002) 1140-1144
142. Terris B., Blaveri E., Crnogorac-Jurcevic T., Jones M., Missiaglia E., Ruszniewski P., Sauvanet A., and Lemoine N.R. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol. 160 (2002) 1745-1754
143. Fine S.W., Lisanti M.P., Galbiati F., and Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am. J. Clin. Pathol. 115 (2001) 719-724
144. Yokomori H., Oda M., Ogi M., Sakai K., and Ishii H. Enhanced expression of endothelial nitric oxide synthase and caveolin-1 in human cirrhosis. Liver 22 (2002) 150-158
145. Yokomori H., Oda M., Yoshimura K., Nomura M., Wakabayashi G., Kitajima M., and Ishii H. Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver: relation with nitric oxide. J. Gastroenterol. 38 (2003) 854-860
146. Yerian L.M., Anders R.A., Tretiakova M., and Hart J. Caveolin and thrombospondin expression during hepatocellular carcinogenesis. Am. J. Surg. Pathol. 28 (2004) 357-364
147. Ip Y.C., Cheung S.T., and Fan S.T. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol. Carcinog. 46 (2007) 225-230
148. Fong A., Garcia E., Gwynn L., Lisanti M.P., Fazzari M.J., and Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 120 (2003) 93-100
149. Kunze E., Von Bonin F., Werner C., Wendt M., and Schlott T. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int. J. Mol. Med. 17 (2006) 3-13
150. Rajjayabun P.H., Garg S., Durkan G.C., Charlton R., Robinson M.C., and Mellon J.K. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58 (2001) 811-814
151. Sanchez-Carbayo M., Socci N.D., Charytonowicz E., Lu M., Prystowsky M., Childs G., and Cordon-Cardo C. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 62 (2002) 6973-6980
152. Yang G., Timme T.L., Frolov A., Wheeler T.M., and Thompson T.C. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103 (2005) 1186-1194
153. Yang G., Truong L.D., Timme T.L., Ren C., Wheeler T.M., Park S.H., Nasu Y., Bangma C.H., Kattan M.W., Scardino P.T., and Thompson T.C. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4 (1998) 1873-1880
154. Yang G., Truong L.D., Wheeler T.M., and Thompson T.C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59 (1999) 5719-5723
155. Savage K., Lambros M.B., Robertson D., Jones R.L., Jones C., Mackay A., James M., Hornick J.L., Pereira E.M., Milanezi F., Fletcher C.D., Schmitt F.C., Ashworth A., and Reis-Filho J.S. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 13 (2007) 90-101
156. Sunaga N., Miyajima K., Suzuki M., Sato M., White M.A., Ramirez R.D., Shay J.W., Gazdar A.F., and Minna J.D. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 64 (2004) 4277-4285
157. Moon K.C., Lee G.K., Yoo S.H., Jeon Y.K., Chung J.H., Han J., and Chung D.H. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res. 25 (2005) 4631-4637
158. Ito Y., Yoshida H., Nakano K., Kobayashi K., Yokozawa T., Hirai K., Matsuzuka F., Matsuura N., Kakudo K., Kuma K., and Miyauchi A. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br. J. Cancer 86 (2002) 912-916
159. Ito Y., Yoshida H., Tomoda C., Uruno T., Takamura Y., Miya A., Kobayashi K., Matsuzuka F., Nakamura Y., Kakudo K., Kuma K., and Miyauchi A. Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma. Pathol. Res. Pract. 201 (2005) 545-549
160. Cassoni P., Senetta R., Castellano I., Ortolan E., Bosco M., Magnani I., and Ducati A. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am. J. Surg. Pathol. 31 (2007) 760-769
161. Barresi V., Cerasoli S., Paioli G., Vitarelli E., Giuffre G., Guiducci G., Tuccari G., and Barresi G. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathol. 112 (2006) 617-626
162. Tirado O.M., Mateo-Lozano S., Villar J., Dettin L.E., Llort A., Gallego S., Ban J., Kovar H., and Notario V. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res. 66 (2006) 9937-9947